Global Reach MiCheck Prostate is commercially available in the US via a high complexity CLIA testing lab in Maryland and in Australia through Sonic Healthcare's pathology network, with ongoing talks to relaunch in other territories. This creates immediate entry points with large-scale pathology networks and reference labs; leverage existing distributors and regulatory footholds to accelerate expansion into additional markets.

Clinical Edge The test achieves high sensitivity and superior specificity, reducing false positives by up to half and lowering unnecessary biopsies, translating into compelling cost savings for healthcare systems. Use ROI and outcomes data to build payer and hospital-side value propositions.

Network Targets Primary sales targets include US high complexity CLIA labs and large pathology networks, plus Sonic-affiliated and equivalent international networks. Leverage the US Laboratory Director appointment and existing distributors to craft localized go-to-market strategies and co-marketing opportunities.

Evidence Driven MiCheck Prostate has published research supporting its diagnostic utility, with ongoing clinical validation and leadership appointments in the US. Compile clinical dossiers, KOL engagement plans, and real-world evidence programs to support adoption in oncology and urology care pathways.

Strategic Partners Past government collaboration in NSW signals potential for payer negotiations and reimbursement pathways. Target health authorities and funding bodies in new territories to align MiCheck Prostate adoption with public health programs and accelerate market entry.